Description
VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose a range of cancers and other diseases.
The Company’s assays are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid. Nu.Q assays are used for the development of Nu.Q blood tests for the prevalent cancers that are focused on lung cancer, colorectal cancer and hematological cancers using its Nucleosomics biomarker discovery platform.
Nu.Q assays are used for the development of Nu.Q blood tests for NETosis. Nu.Q Capture technology to isolate nucleosomes containing particular epigenetic signals or structures for complete analysis by mass spectrometry, deoxyribonucleic acid (DNA) sequencing, immunoassays or other methods for a range of scientific and medical applications.
